Background: We observed two cases of patients with schizophrenia who were treated with clozapine (250mg/day and 275mg/day, respectively) and showed neutropenia after receiving a COVID-19 vaccine (BNT162b2).
Case Presentation: Case 1 is a twenty-two year old woman with a diagnosis of schizophrenia. She enrolled in Clozaril Patient Monitoring Service in 2017 and had been taking clozapine for 4 years. She received two doses of a COVID-19 vaccine and developed neutropenia (1850/mm (37.9% of white blood cell 4880/mm)) 6 days after the second vaccination, but her neutropenia self-resolved naturally. Case 2 is a twenty year old woman with a diagnosis of schizophrenia. She enrolled in Clozaril Patient Monitoring Service in 2020 and had been taking clozapine for 10 months. She received two doses of a COVID-19 vaccine and white blood cell and neutrocyte counts were below (3730/mm and 1440/mm (38.6%), respectively) the lower limits 3 days after the second vaccination. She had to discontinue clozapine according to the withdrawal definition (her neutrocyte count was <1500/mm), and her neutropenia self-resolved naturally.
Conclusion: Physicians need to have a strict follow-up protocol in place for patients after vaccination for COVID-19.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8805838 | PMC |
| http://dx.doi.org/10.2147/IMCRJ.S350879 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunogenicity of bivalent versus monovalent mRNA booster vaccination among adult paramedics in Canada who had received three prior mRNA wild-type doses.
Access Microbiol
January 2025
Department of Emergency Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Comparative immunogenicity from different mRNA booster vaccines (directed at WT, BA.1 or BA.4/5 antigens) remains unclear.
View Article and Find Full Text PDFDisparities in response to mRNA SARS-CoV-2 vaccines according to sex and age: A systematic review.
New Microbes New Infect
February 2025
Department of Global and Public Health, Epidemiology, Biostatistics and Prevention Institute, WHO Collaborating Centre for Travellers' Health, Centre of Competence for Military Medicine Biology, University of Zürich, Switzerland.
Background: The rapid development and distribution of mRNA COVID-19 vaccines has been essential in containing the SARS-CoV-2 epidemic around the globe. For ongoing and future immunization campaigns globally, there is a need to evaluate the impact of population demographics such as age and sex, on vaccine efficacy and safety.
Methods: This systematic review (PROSPERO ID CRD42023328245) conducted according to PRISMA guidelines evaluates the impact of age and sex on the safety and efficacy of the mRNA COVID-19 vaccinations administrated in 15 studies that were chosen according to strict criteria.
Balancing mitigation strategies for viral outbreaks.
Math Biosci Eng
December 2024
Department of Mathematics & Statistics, Georgia State University, Atlanta, USA.
Control and prevention strategies are indispensable tools for managing the spread of infectious diseases. This paper examined biological models for the post-vaccination stage of a viral outbreak that integrate two important mitigation tools: social distancing, aimed at reducing the disease transmission rate, and vaccination, which boosts the immune system. Five different scenarios of epidemic progression were considered: (ⅰ) the "no control" scenario, reflecting the natural evolution of a disease without any safety measures in place, (ⅱ) the "reconstructed" scenario, representing real-world data and interventions, (ⅲ) the "social distancing control" scenario covering a broad set of behavioral changes, (ⅳ) the "vaccine control" scenario demonstrating the impact of vaccination on epidemic spread, and (ⅴ) the "both controls concurrently" scenario incorporating social distancing and vaccine controls simultaneously.
View Article and Find Full Text PDFCurrent Scenario in Associating Clinical COVID-19 Biomarkers for Developing Surveillance Platforms.
Curr Med Chem
January 2025
Department of Physics, Kalasalingam Academy of Research and Education, Krishnankoil, Virudhunagar, Tamil Nadu, 626126, India.
The novel coronavirus that caused the epidemic and pandemic resulting in the acute respiratory illness known as coronavirus disease 2019 (COVID-19) has plagued the world. This is unlike other coronavirus outbreaks that have occurred in the past, such as Middle East respiratory syndrome (MERS) or severe acute respiratory syndrome (SARS). COVID-19 has spread more quickly and posed special challenges due to the lack of appropriate treatments and vaccines.
View Article and Find Full Text PDF[Optimize surveillance, prevention and control, vaccine strategies to respond to seasonal epidemics of respiratory infectious diseases].
Zhonghua Yi Xue Za Zhi
January 2025
Public Health Emergency Management Innovation Center, Key Laboratory of Pathogen Infection Prevention and Control (Peking Union Medical College), Ministry of Education, State Key Laboratory of Respiratory Health and Multimorbidity, School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing100730, China.
The prevalence and evolution of respiratory pathogens are changing, and issues related to drug-resistance are becoming increasingly prominent in the post-COVID era. The urgency of controlling respiratory pathogens has intensified. This issue organizes expert discussions to address the resurgence of various respiratory pathogens, summarizing current status of pathogen surveillance, drug-resistance research and vaccine development, while suggesting countermeasures.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!